Drug Profile
Research programme: DABOs - Idenix
Alternative Names: DABOs research programme - Idenix; Topical anti-HIV agents research programme - IdenixLatest Information Update: 16 Jul 2007
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals; University of Cagliari; University of Rome
- Class
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 23 May 2006 No development reported - Preclinical for HIV infections prevention in France (Topical)
- 23 May 2006 No development reported - Preclinical for HIV infections prevention in Italy (Topical)
- 23 May 2006 No development reported - Preclinical for HIV infections prevention in USA (Topical)